TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
大正製薬ホールディングス株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4581
No filings in 18+ monthsFY2022 (Mar 2023) · J-GAAP · consolidated Source: filing S100R80T
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2022 (Mar 2023) runs Apr 1, 2022 – Mar 31, 2023.
| Gross margin | 59.0% |
|---|---|
| Operating margin | 7.6% |
| Net margin | 6.3% |
| Return on equity | 2.5%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 2.1% |
| Revenue growth (YoY) | 12.4% |
| EPS (basic) | ¥231.73 |
| EPS growth (YoY) | 43.8% |
| Current ratio | 5.09x |
| Equity ratio | 83.5% |
| Book value / share | ¥9,584.70 |
| Free cash flow | −¥9.4B |